---
title: "Medicare Expansion of GLP-1 Access: Projected 10-Year Health and Economic Impact"
id: "medrxiv-6-projected-health-and-economic-effects-of-expanded-access-to-anti-obesity"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-projected-health-and-economic-effects-of-expanded-access-to-anti-obesity"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1?rss=1"
published_at: "2026-10-28T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Medicare Expansion of GLP-1 Access: Projected 10-Year Health and Economic Impact
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-projected-health-and-economic-effects-of-expanded-access-to-anti-obesity
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1?rss=1)
- **Published At:** 2026-10-28T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators used the **Future Elderly Model**, a microsimulation of Americans aged 55+, to estimate 10-year costs and benefits of expanded Medicare access to **GLP-1** therapies under the CMS GLP-1 Bridge demonstration. - The Bridge demonstration (July 2026–December 2027) offers additional Part D beneficiaries access to GLP-1s with a $50 monthly copay; authors modeled continuation of that access over a decade and a reduced GLP-1 price for existing Part D indications beginning in 2028. - Two uptake/persistence scenarios were simulated: a high discontinuation/high reinitiation pattern (Rodriguez et al.) and a low discontinuation/low reinitiation pattern (Understanding America Study); each was run under a broad and a narrow definition of Bridge eligibility. - Expanded access produced positive **net social value** in every modeled scenario, with authors reporting aggregate 10-year social value ranging from $44.3 billion to $58.5 billion. - From Medicare's perspective, cumulative net spending fell in all scenarios; reported Medicare savings ranged between $21.2 billion and $27.1 billion over 10 years, which included $31.9 billion in diabetes drug price savings attributable to the assumed pricing change. - Return on investment varied by perspective: Medicare ROI was reported at 117–216%, while societal ROI was reported at 198–346% across scenarios. - The definition of the eligible population influenced results more than assumptions about persistence: the narrow eligibility definition produced 23–29% higher net social value because initiators were healthier and had greater gains. - Low discontinuation increased net social value modestly (2–7%) but raised Medicare drug spending; accordingly, ROI to Medicare was higher under the high-discontinuation scenario. - The authors emphasized that short-term evaluation confined to the 18-month demonstration window would understate benefits because health gains accrue over many years. - The study used publicly available inputs (Health and Retirement Study, Medicare Current Beneficiary Survey, Understanding America Study); data and model technical documentation are available on request, per the authors.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=S0Ai4jUNUzSttQEza82vwceE.UYz5_rXPM3gfvLxcho-1793243094.7955923-1.2.1.1-0dth4SV11tMLaalMT.diURIqVgaF8Q6yHqIHdD0w8DGYBIx8T6HnSdfMKMjSuI9Y) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Projected Health and Economic Effects of Expanded Access to Anti-Obesity Medications in Medicare [ View ORCID Profile](http://orcid.org/0000-0002-9614-4089)Alison Sexton Ward, [ View ORCID Profile](http://orcid.org/0000-0003-1638-1584)PhuongGiang Nguyen, [ View ORCID Profile](http://orcid.org/0000-0003-1543-9449)Jack Chapel, [ View ORCID Profile](http://orcid.org/0000-0002-8497-3664)Bryan Tysinger, [ View ORCID Profile](http://orcid.org/0000-0002-8736-7862)Erin Trish, [ View ORCID Profile](http://orcid.org/0000-0001-5934-8042)Darius Lakdawalla, [ View ORCID Profile](http://orcid.org/0000-0001-8498-6396)Dana Goldman doi: https://doi.org/10.64898/2026.10.26.26366542 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Alison Sexton Ward Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alison%2BSexton%2BWard%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sexton%20Ward%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlison%2BSexton%2BWard%2B) * [ORCID record for Alison Sexton Ward](http://orcid.org/0000-0002-9614-4089 "Open in new tab") * For correspondence: sextonwa@usc.edu PhuongGiang Nguyen Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=PhuongGiang%2BNguyen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nguyen%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APhuongGiang%2BNguyen%2B) * [ORCID record for PhuongGiang Nguyen](http://orcid.org/0000-0003-1638-1584 "Open in new tab") Jack Chapel Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jack%2BChapel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chapel%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJack%2BChapel%2B) * [ORCID record for Jack Chapel](http://orcid.org/0000-0003-1543-9449 "Open in new tab") Bryan Tysinger Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Bryan%2BTysinger%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tysinger%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABryan%2BTysinger%2B) * [ORCID record for Bryan Tysinger](http://orcid.org/0000-0002-8497-3664 "Open in new tab") Erin Trish Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Erin%2BTrish%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Trish%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AErin%2BTrish%2B) * [ORCID record for Erin Trish](http://orcid.org/0000-0002-8736-7862 "Open in new tab") Darius Lakdawalla Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Darius%2BLakdawalla%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lakdawalla%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADarius%2BLakdawalla%2B) * [ORCID record for Darius Lakdawalla](http://orcid.org/0000-0001-5934-8042 "Open in new tab") Dana Goldman Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dana%2BGoldman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Goldman%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADana%2BGoldman%2B) * [ORCID record for Dana Goldman](http://orcid.org/0000-0001-8498-6396 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1332664/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1332664/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1332664/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1332664/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1332664/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: The CMS GLP-1 Bridge demonstration (July 2026-December 2027) expands access to GLP-1s for additional eligible Medicare Part D beneficiaries for a $50 monthly copay. Its long-run value depends on uptake, discontinuation, and which beneficiaries initiate therapy, in addition to policy decisions. Methods: We used the Future Elderly Model, a microsimulation of Americans aged 55 and older, to model the costs and benefits of expanded GLP-1 access to the newly Bridge-eligible population, assuming that it continues over a 10-year horizon and is accompanied by reduced GLP-1 pricing taking effect for already covered indications in Part D beginning in 2028. We compared a status quo with two expanded-access scenarios: high discontinuation paired with high reinitiation (Rodriguez et al.), and low discontinuation paired with low reinitiation (Understanding America Study). Each scenario was run for two different definitions of the Bridge-eligible population - a broad definition that includes beneficiaries with prior myocardial infarction or stroke and a narrow definition that excludes them. Results: Expanded access generated positive net social value in every scenario, from $44.3 billion to $58.5 billion over 10 years. Medicare net spending fell in every scenario, with cumulative savings of $21.2 - 27.1 billion, including $31.9 billion in diabetes drug price savings. Return on investment was 117 - 216% for Medicare and 198 - 346% for society. The eligible population mattered more than persistence. Net social value was 23 - 29% higher in the narrow population, because its initiators are healthier and have more to gain form access to GLP-1 treatment. Low discontinuation raised net social value by only 2 - 7% but raised Medicare drug spending, so ROI was higher under high discontinuation. Conclusions: Expanded Medicare access to GLP-1s is projected to produce substantial social value across a range of persistence and eligibility assumptions. Extending the lower demonstration price to previously covered indications would allow the program to pay for itself from Medicare's perspective. Because health gains accrue over many years, evaluating the demonstration only over its 18-month window would understate its benefits. ### Competing Interest Statement This paper was supported by the Schaeffer Center, which receives funding from foundations, government agencies - including CMS contract #75FCMC26C0008, individuals, and corporations - including companies that have interests in obesity treatments. A complete list of supporters of the Schaeffer Center can be found in our annual report. The Future Adult Model was developed with support from the National Institute on Aging (P30AG024968). At all times, the independence and integrity of the research is paramount, and the Center retains the right to publish all findings from its research activities. The views expressed herein are those of the authors and do not necessarily represent the views of the Schaeffer Center or its sponsors. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Our simulation model uses data from three publically available sources: (1) Health and Retirement Study: https://hrsdata.isr.umich.edu/data-products/public-survey-data (2) Medicare Current Beneficiary Survey: https://www.cms.gov/data-research/research/medicare-current-beneficiary-survey (3) Understanding America Study: https://uasdata.usc.edu/page/Data+Products I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.27.26366576v1 "Post-implantation 3-T MRI in patients with an epicranial stimulation device: image quality and deep learning-based electrode reconstruction")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.26.26366545v1 "Where did it go? How Information Management Practices Impact Rigor and Reproducibility in Collaborative Clinical and Translational Research") Posted October 28, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/28/2026.10.26.26366542.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.10.26.26366542v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/28/2026.10.26.26366542.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Projected Health and Economic Effects of Expanded Access to Anti-Obesity Medications in Medicare Alison Sexton Ward, PhuongGiang Nguyen, Jack Chapel, Bryan Tysinger, Erin Trish, Darius Lakdawalla, Dana Goldman medRxiv 2026.10.26.26366542; doi: https://doi.org/10.64898/2026.10.26.26366542 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.26.26366542v1%26text%3DProjected%2520Health%2520and%2520Economic%2520Effects%2520of%2520Expanded%2520Access%2520to%2520Anti-Obesity%2520Medications%2520in%2520Medicare "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.26.26366542v1%26t%3DProjected%2520Health%2520and%2520Economic%2520Effects%2520of%2520Expanded%2520Access%2520to%2520Anti-Obesity%2520Medications%2520in%2520Medicare "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.26.26366542v1%26title%3DProjected%2520Health%2520and%2520Economic%2520Effects%2520of%2520Expanded%2520Access%2520to%2520Anti-Obesity%2520Medications%2520in%2520Medicare%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.10.26.26366542v1%26title%3DProjected%2520Health%2520and%2520Economic%2520Effects%2520of%2520Expanded%2520Access%2520to%2520Anti-Obesity%2520Medications%2520in%2520Medicare "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.10.26.26366542) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.10.26.26366542v1&count=horizontal&via=&text=Projected%20Health%20and%20Economic%20Effects%20of%20Expanded%20Access%20to%20Anti-Obesity%20Medications%20in%20Medicare&counturl=www.medrxiv.org/content/10.64898/2026.10.26.26366542v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (637) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (915) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (348) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4962) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (492) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (426) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (674) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1678) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16188) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1237) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7238) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (750) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1092) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5246) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1461) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1820) * [Hematology](https://www.medrxiv.org/collection/hematology) (598) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1374) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16451) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1197) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (693) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (742) * [Neurology](https://www.medrxiv.org/collection/neurology) (7541) * [Nursing](https://www.medrxiv.org/collection/nursing) (376) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1118) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1292) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1036) * [Oncology](https://www.medrxiv.org/collection/onc
## Related Clinical Research

- [Cardiovascular safety of oral orforglipron versus insulin glargine in T2D at increased CV risk (AC](https://medichelpline.com/clinical-feed/pubmed-42815506.md) (DOI: 10.1016/S0140-6736(26)01865-9)
- [Compare and Contrast: GLP-1 Receptor Agonists Access and Cardiovascular Outcomes](https://medichelpline.com/clinical-feed/endocrine-news-33-compare-and-contrast-as-glucagon-like-peptide-1-receptor-agonist-access-expands-comparative-heart-outcomes-matter.md)
- [Cardiovascular outcomes of GLP-1 receptor agonists: systematic review findings](https://medichelpline.com/clinical-feed/pubmed-42033237.md) (DOI: 10.1093/ajhp/zxag121)
- [Novartis pelacarsen cuts Lp(a) but fails to reduce major cardiovascular events](https://medichelpline.com/clinical-feed/stat-news-0-stat-failure-of-novartis-lp-a-drug-raises-questions-about-cardiovascular.md)
- [GLP-1 RAs on Top of Statins Linked to Lower Mortality, MI, and Stroke in ASCVD with Obesity](https://medichelpline.com/clinical-feed/medrxiv-0-glp-1-receptor-agonists-added-to-statin-therapy-and-cardiovascular-outcomes-in.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.